TMO · Q2 2026 Earnings

Bullish

Thermo Fisher Scientific

Reported July 23, 2026

30-second summary

Q2 organic revenue growth came in at 5%, two full points above the ~3% Casper telegraphed on the Q1 call, with revenue of $11.99B (+10.5% YoY) and adjusted EPS of $6.03 (+13% YoY). Management left the FY2026 guide unchanged in the press release ($47.3–$48.1B revenue, $24.64–$25.12 adjusted EPS, 3–4% organic) but deferred the formal update to the earnings call, signalling a raise is coming. The Q1 credibility gap — 1% organic vs. a 3–4% FY commitment — is now materially closed with a single quarter, and Analytical Instruments returned to positive organic territory.

Headline numbers

EPS

Q2 FY2026

$6.03

+5.6% vs est.

Revenue

Q2 FY2026

$11.99B

+10.5% YoY

+2.5% vs est.

Gross margin

Q2 FY2026

41.2%

Free cash flow

Q2 FY2026

$1.68B

Operating margin

Q2 FY2026

17.4%

Key financials

Q2 FY2026

Metric	Q2 FY2026	Q2 FY2025	YoY	Q1 FY2026	QoQ
Revenue	$11.99B	$10.86B	+10.5%	$11.01B	+8.9%
EPS	$6.03	$5.36	+12.5%	$5.44	+10.8%
Gross margin	41.2%	41.2%	+0bps	40.7%	+50bps
Operating margin	17.4%	16.9%	+50bps	16.9%	+50bps
Free cash flow	$1.68B	$1.10B	+51.9%	$0.82B	+103.4%

Guidance

Strong Q2 beat on revenue and EPS with organic growth of 5% exceeding guidance; full-year FY2026 guidance reaffirmed as company intends to provide updated 2026 guidance on earnings call.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q2 FY2026	~3% organic growth (prior quarter guide for Q2 implied ~$11.6B based on Q1 run-rate)	$11.994B	+2.5% above consensus; +10.5% YoY	Beat
Adjusted EPS	Q2 FY2026	25–30 cents higher than Q1 (Q1 non-GAAP EPS implied ~$5.75, so Q2 guide ~$6.00–$6.05)	$6.03	+5.6% above consensus ($5.71)	Beat
Organic Revenue Growth	Q2 FY2026	about 3%	5%	+2 percentage points above guide	Beat

New guidance

Metric	Period	Guide	YoY
Adjusted Operating Margin	Q2 FY2026	22.8%	—
Free Cash Flow	Q2 FY2026	$1.678B	—

Reaffirmed unchanged this quarter: Revenue ($47.3B to $48.1B), Adjusted EPS ($24.64 to $25.12), Organic Revenue Growth (3% to 4%)

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Life Sciences Solutions	$2.815B	$2.499B	+12.6%
Analytical Instruments	$1.847B	$1.728B	+6.9%
Specialty Diagnostics	$1.205B	$1.134B	+6.3%
Laboratory Products and Biopharma Services	$6.693B	$5.995B	+11.6%

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Organic Revenue Growth	5%	2%	—
Adjusted Operating Margin	22.8%	21.9%	—
Life Sciences Solutions Segment Margin	37.0%	36.8%	—
Analytical Instruments Segment Margin	23.0%	—	—
Specialty Diagnostics Segment Margin	27.7%	27.0%	—
Laboratory Products and Biopharma Services Segment Margin	14.0%	—	—
Free Cash Flow	$1.678 billion	—	—
Share Repurchases	$1.0 billion	—	—

Management tone

No transcript was available at time of writing; prepared remarks and Q&A commentary will be incorporated into the next brief. The observations below are drawn from the press release framing only.

Q1-25 macro defensiveness → Q2-25 explicit 2026–2027 valley framework → Q3-25 execution-driven raise → Q4-25 quantified 2026 inflection → Q1-26 active management through inflation → Q2-26 quiet delivery.

The Casper quote in the press release — "At the halfway point of the year, we are well positioned to deliver a great 2026 and build an even brighter future for our company" — is materially less hedged than Q1's "navigating a complex macro environment" framing. The decision to defer the formal FY guidance update to the call rather than pre-print it in the release is itself the tone signal: management is holding back the number for delivery in a controlled setting, which is what companies do when the update is meaningful. A no-change guide would typically appear in the press release.

Answers to last quarter's watch list

Whether Q2 organic growth delivers the guided ~3% — Delivered 5%, two full points above guide and the strongest organic print in the current cycle. This is the cleanest possible resolution to the Q1 credibility question and materially de-risks the FY 3–4% commitment. Status: Resolved positively

Analytical Instruments inflection from -2% Q1 organic — Segment grew +6.9% reported in Q2 vs. Q1's -0.1% reported / -2% organic, decisively breaking the three-quarter deceleration trend. Organic figure not disclosed in the press release but the reported jump is unambiguous. Status: Resolved positively

Whether LPBS segment margin of 12.9% was a Clario consolidation artifact — Q2 LPBS margin recovered to 14.0%, +110bps from Q1 and within striking distance of Q4-25's 14.5% baseline. The Q1 compression was largely a first-week integration artifact, not a structural mix shift. Status: Resolved positively

FCF conversion trajectory — Q2 FCF of $1.68B is roughly double Q1's $0.83B and brings H1 to $2.50B. FCF/net income conversion in Q2 was ~97% ($1.68B FCF vs. $1.74B net income), a material step-up from Q1's ~50%. The FY $6.9–$7.4B guide still requires a strong H2 (~$4.4B+ needed), but the Q2 conversion improvement is exactly what was needed. Status: Continue monitoring

May 20 analyst day disclosures on AI partnership architecture and 7%+ long-term algorithm reaffirmation — Analyst day content is not addressed in the Q2 press release. Status: Not resolved

Reshoring revenue recognition timing — Not addressed in the press release; awaiting transcript. Status: Not resolved

What to watch into next quarter

The formal FY2026 guidance update on the earnings call — specifically whether revenue, organic growth, and adjusted EPS get raised, and by how much. A revenue raise of less than $300M midpoint or an organic band left at 3–4% would be a disappointment given the Q2 outperformance; the market is set up for +$500M–$700M revenue and organic to 4–5%.

Whether Analytical Instruments' +6.9% Q2 reported growth translates to positive organic growth (not disclosed in the release) and whether the underlying sub-segments (mass spec, cryo-EM, chromatography) show durable strength or a one-quarter comp-driven bounce.

H2 FCF conversion — $4.4B+ needed across Q3+Q4 to hit the FY $6.9–$7.4B guide midpoint. Q3 FCF below $2.0B puts the FY at risk.

Adjusted operating margin progression — Q2 at 22.8% is tracking toward the FY +70bps expansion, but Q3 has historically been the softer margin quarter; watch for whether tariff/FX headwinds Casper quantified at 80bps in Q1 have narrowed further.

Clario integration commentary at full-quarter run rate — the segment margin recovery is encouraging, but explicit disclosure of Clario's revenue contribution and organic-vs-M&A decomposition in LPBS is needed to separate operational strength from acquisition math.

China and academic/government commentary — Q1 had China better than the mid-single-digit-decline assumption and academic/government "muted." Watch whether either end market has meaningfully improved or whether the strong Q2 print was driven entirely by pharma/biotech and bioproduction.

Sources

Thermo Fisher Q2 2026 Earnings 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/97745/000009774526000138/q22026earnings8kex99_1.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.